Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Surgical Oncology · Invasive Ductal Carcinoma of the Breast

Building Your Care Team and Preparing for Your First Visit

At a Glance

For a first invasive ductal carcinoma visit, bring original imaging, pathology, operative, and genetic records and ask how specialists will coordinate care. Discuss inherited-DNA testing, fertility preservation before treatment, and how your priorities should shape decisions.

Navigating the first few weeks after a breast cancer diagnosis can feel like a full-time job. You are transitioning from being a person with a “suspicious finding” to a patient at the center of a complex medical network. The most effective care for Invasive Ductal Carcinoma (IDC) is multidisciplinary, meaning a team of specialists works together to tailor a plan specifically for you, rather than each doctor working in isolation [1][2].

Your Multidisciplinary Care Team

Your team is a “roundtable” of experts, each viewing your cancer through a different lens [3]:

  • Surgical Oncologist: This doctor specializes in removing the cancer and checking your lymph nodes. They help you decide between a lumpectomy and a mastectomy [4].
  • Medical Oncologist: This specialist manages systemic treatments like chemotherapy, hormone therapy, and targeted drugs. They are often the “captain” of your long-term care [5].
  • Radiation Oncologist: If your treatment includes radiation to the breast or lymph nodes, this doctor will design that plan [6].
  • Plastic & Reconstructive Surgeon: If you choose a mastectomy, this surgeon works alongside your surgical oncologist to rebuild the breast tissue, often during the same surgery [7].
  • Genetic Counselor: They help you understand if your cancer is linked to an inherited gene mutation, which can change your surgical and medical options [8].
  • Nurse Navigator: This is your “air traffic controller.” They help schedule appointments, explain terms, and ensure no part of your plan falls through the cracks [9].
  • Social Work & Financial Navigation: These specialists help navigate insurance costs, work support, mental health, and transportation.

The “Source Materials”: What to Bring

To provide a true second opinion or a comprehensive first visit, your team needs the original data, not just the summaries. Research shows that a multidisciplinary review of these materials often leads to changes in the diagnosis or treatment plan [10].

  • Imaging Discs: Ask for your mammograms, ultrasounds, and MRIs on a CD or via an electronic DICOM transfer. The doctors need to see the actual images, not just the typed report [5].
  • Pathology Slides: If you had your biopsy at a different hospital, your new team may want their own pathologists to look at the physical tissue (slides or blocks) to confirm the grade and receptor status [11].
  • Complete Reports: Bring physical or digital copies of every pathology report, operative report (if you’ve had surgery), and genetic test result [12].

The Critical Role of Genetic Testing

Current guidelines from ASCO and the Society of Surgical Oncology (SSO) recommend offering germline genetic testing (testing the DNA you were born with) to newly diagnosed breast cancer patients aged 65 or younger, as well as older people who meet selective criteria [13]. This testing typically looks for mutations in genes like BRCA1, BRCA2, and PALB2 [8].

Knowing your genetic status early is critical for two reasons:

  1. Surgical Planning: If you carry a BRCA1/2 or PALB2 mutation, you may have a much higher risk of developing a second cancer in either breast. This often prompts a discussion about risk-reducing contralateral mastectomy, though breast-conserving surgery with enhanced surveillance remains a valid and appropriate option for many carriers based on age and preferences [14][15].
  2. Drug Eligibility: Some modern targeted therapies, such as PARP inhibitors, are specifically indicated for selected germline-BRCA carriers with HER2-negative cancers in particular settings [13][16].

Protecting Your Future: Fertility and Pregnancy

If you are premenopausal and considering a future pregnancy, fertility preservation must be discussed before you start chemotherapy or certain hormone treatments [17]. Chemotherapy can damage the ovaries, and hormone therapies are often taken for 5 to 10 years, which may delay pregnancy during your childbearing years [18][19].

Your oncology team should provide an urgent referral to a Reproductive Endocrinologist. Common options include:

  • Oocyte or Embryo Cryopreservation: Freezing eggs or fertilized embryos before treatment is established and can often be arranged rapidly, though it must be closely coordinated with cancer treatment [18][20].
  • GnRH Agonists: Injections (like Zoladex) given during chemotherapy that may help improve the chance of ovarian-function recovery. However, they do not guarantee future fertility and are not a substitute for egg or embryo freezing [17][21].
  • Contraception: It is vital to avoid pregnancy during active cancer treatment; non-hormonal contraception planning should be part of this discussion.

Embracing Shared Decision-Making

You are the most important member of your care team. Shared decision-making is a process where your doctors provide the evidence and you provide your values and preferences [22]. Do not be afraid to ask for a “Tumor Board” review, where the entire team meets behind the scenes to discuss your case and reach a consensus on the best path forward [1][2].

Common questions in this guide

Who should be on my invasive ductal carcinoma care team?
Your team may include a surgical oncologist, medical oncologist, and radiation oncologist. A plastic and reconstructive surgeon, genetic counselor, nurse navigator, social worker, and financial navigator may join based on your needs. These professionals coordinate recommendations rather than making decisions in isolation.
What should I bring to my first breast cancer appointment?
Bring original mammogram, ultrasound, or MRI images on a disc or through a secure upload in DICOM format, along with pathology slides or tissue blocks when available. Also bring complete pathology, operative, and genetic test reports. Original materials let the new team review the evidence directly and can support a second opinion.
Should I have genetic testing after an invasive ductal carcinoma diagnosis?
Guidelines recommend offering testing of inherited DNA to many newly diagnosed breast cancer patients aged 65 or younger and to some older patients who meet additional criteria. Testing often includes BRCA1, BRCA2, and PALB2. Results can affect surgical planning and whether certain targeted treatments are appropriate.
How could a BRCA or PALB2 result change my surgery?
An inherited BRCA1, BRCA2, or PALB2 mutation can raise the risk of a new cancer in either breast. Your team may discuss risk-reducing removal of the opposite breast, but lumpectomy with closer monitoring remains an appropriate choice for many people. The decision depends on medical factors, age, and your preferences.
When should I discuss fertility preservation?
If you may want a future pregnancy, discuss fertility preservation before chemotherapy or certain hormone treatments begin. Ask for an urgent referral to a reproductive endocrinologist; freezing eggs or embryos may be arranged quickly. Medicines called GnRH agonists may help ovarian recovery during chemotherapy but do not guarantee future fertility and do not replace egg or embryo freezing.
What is a breast tumor board, and can my case be reviewed?
A tumor board is a meeting where specialists review your diagnosis and treatment options together. You can ask whether your case will be discussed at a formal breast tumor board and how its recommendations will be shared with you. The review can help the team reach a coordinated plan.
How can I make sure my breast cancer doctors communicate with one another?
Ask who coordinates your care, such as a nurse navigator, and how the surgeon, medical oncologist, and radiation oncologist exchange records and recommendations. You can also ask whether your facility has a shared patient portal for imaging and reports. A clear point of contact can help prevent missed appointments or gaps in the plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Who is the designated coordinator for my multidisciplinary team, and will my case be reviewed at a formal breast tumor board?
  2. 2.Which genetic testing panel are you ordering for me, and will the results be available before we finalize my surgical plan?
  3. 3.If I carry a BRCA or PALB2 mutation, how does that specifically change my options for lumpectomy versus mastectomy?
  4. 4.Can you provide a referral to a reproductive endocrinologist before we start any chemotherapy or hormone treatments?
  5. 5.How does your team coordinate communication between the surgeon, medical oncologist, and radiation oncologist to ensure my treatment is seamless?
  6. 6.Does your facility have an image portal where I can upload my DICOM files, or do I need to bring physical discs to every appointment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    The Approach to Multidisciplinary Oncologic Breast Care.

    Owens WR, Ding Y, Quirarte DM, et al.

    Seminars in plastic surgery 2025; (39(2)):97-102 doi:10.1055/s-0045-1806808.

    PMID: 40406634
  2. 2

    Multidisciplinary meeting for breast cancer care: EUSOMA recommendations for optimization.

    Curigliano G, Marotti L, Barrios C, et al.

    Breast (Edinburgh, Scotland) 2026; (85()):104682 doi:10.1016/j.breast.2025.104682.

    PMID: 41496426
  3. 3

    Multidisciplinary team approach in breast cancer care: Benefits and challenges.

    Blackwood O, Deb R

    Indian journal of pathology & microbiology 2020; (63(Supplement)):S105-S112 doi:10.4103/IJPM.IJPM_885_19.

    PMID: 32108641
  4. 4

    Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

    Korde LA, Somerfield MR, Carey LA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

    PMID: 33507815
  5. 5

    Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    Burstein HJ, Curigliano G, Thürlimann B, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2021; (32(10)):1216-1235 doi:10.1016/j.annonc.2021.06.023.

    PMID: 34242744
  6. 6

    Consensus statement on tumour bed localization for radiation after oncoplastic breast surgery.

    Tse T, Knowles S, Bélec J, et al.

    Current oncology (Toronto, Ont.) 2020; (27(3)):e326-e331 doi:10.3747/co.27.5977.

    PMID: 32669940
  7. 7

    Oncoplastic breast surgery: A guide to good practice.

    Gilmour A, Cutress R, Gandhi A, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2021; (47(9)):2272-2285 doi:10.1016/j.ejso.2021.05.006.

    PMID: 34001384
  8. 8

    Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.

    Manahan ER, Kuerer HM, Sebastian M, et al.

    Annals of surgical oncology 2019; (26(10)):3025-3031 doi:10.1245/s10434-019-07549-8.

    PMID: 31342359
  9. 9

    Impact of Patient Navigation on Radiation Therapy Completion in Black Breast Cancer Patients: Early Phase I Trial Results From the Navigator-Assisted Hypofractionation (NAVAH) Program.

    McClelland S, Burnette U, Onyewadume L, et al.

    American journal of clinical oncology 2026; (49(3)):125-126 doi:10.1097/COC.0000000000001257.

    PMID: 41091946
  10. 10

    The Impact of Tumor Boards on Breast Cancer Care: Evidence from a Systematic Literature Review and Meta-Analysis.

    Di Pilla A, Cozzolino MR, Mannocci A, et al.

    International journal of environmental research and public health 2022; (19(22)) doi:10.3390/ijerph192214990.

    PMID: 36429708
  11. 11

    Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.

    Faragalla H, Plotkin A, Barnes P, et al.

    Current oncology (Toronto, Ont.) 2023; (30(3)):3079-3090 doi:10.3390/curroncol30030233.

    PMID: 36975446
  12. 12

    Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.

    D'Aloisio AA, Nichols HB, Hodgson ME, et al.

    BMC cancer 2017; (17(1)):692 doi:10.1186/s12885-017-3686-6.

    PMID: 29058598
  13. 13

    Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.

    Bedrosian I, Somerfield MR, Achatz MI, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(5)):584-604 doi:10.1200/JCO.23.02225.

    PMID: 38175972
  14. 14

    Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.

    Apostolova C, Ferroum A, Alhassan B, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2024; (50(6)):108324 doi:10.1016/j.ejso.2024.108324.

    PMID: 38636249
  15. 15

    Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

    Tischkowitz M, Balmaña J, Foulkes WD, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(8)):1416-1423 doi:10.1038/s41436-021-01151-8.

    PMID: 33976419
  16. 16

    PARP Inhibitors for Breast Cancer Treatment: A Review.

    Morganti S, Marra A, De Angelis C, et al.

    JAMA oncology 2024; (10(5)):658-670 doi:10.1001/jamaoncol.2023.7322.

    PMID: 38512229
  17. 17

    Fertility Preservation in People With Cancer: ASCO Guideline Update.

    Su HI, Lacchetti C, Letourneau J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(12)):1488-1515 doi:10.1200/JCO-24-02782.

    PMID: 40106739
  18. 18

    Comparison of Fertility-Related Recommendations Across National Comprehensive Cancer Network, ASCO, Clinical Oncology Society of Australia, and European Society for Medical Oncology Guidelines for People With Cancer Comparing Fertility Recommendations for People With Cancer.

    Bhinder JK, Peera M, Al-Khaifi M

    JCO oncology practice 2026; OP2500545 doi:10.1200/OP-25-00545.

    PMID: 41534015
  19. 19

    FERTILITY PRESERVATION IN YOUNG WOMEN WITH EARLY-STAGE BREAST CANCER.

    Vuković P, Kasum M, Raguž J, et al.

    Acta clinica Croatica 2019; (58(1)):147-156 doi:10.20471/acc.2019.58.01.19.

    PMID: 31363337
  20. 20

    Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.

    D'Hondt C, Vanhoeij M, Van Moer E, et al.

    Breast cancer research and treatment 2020; (184(2)):433-444 doi:10.1007/s10549-020-05858-1.

    PMID: 32794060
  21. 21

    Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis.

    Li ZY, Dong YL, Cao XZ, et al.

    Menopause (New York, N.Y.) 2022; (29(9)):1093-1100 doi:10.1097/GME.0000000000002019.

    PMID: 35917530
  22. 22

    Adherence to Multidisciplinary Tumor Board (MTB) Recommendations in Patients With Breast Cancer: The Results From Two Cancer Centers in Germany.

    Kandemir EA, Adam R, Roeper J, et al.

    Clinical breast cancer 2025; (26(1)):13-21 doi:10.1016/j.clbc.2025.10.010.

    PMID: 41265066

This page is for informational purposes and does not replace medical advice. Your breast cancer team should interpret your records and genetic results and guide decisions about treatment, fertility, and pregnancy.

Get notified when new evidence is published on breast ductal adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.